Clinical Trials Browser

Phase 1/2 × Stomach Neoplasms × tremelimumab × Clear all

NCT03751761 2024-02-28

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms